Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT

Overview

The purpose of this study is to reduce the risk of cancer relapse by giving a donor lymphocyte infusion (DLI) to boost the immune system early after a stem cell transplant so that leukemia cells that escaped chemotherapy can be detected and killed. This DLI will contain mostly lymphocytes that have graft versus tumor effect with low risk of graft versus host disease. Because the process of giving a DLI in the first four weeks after a transplant has not been approved by the Food and Drug Administration (FDA), this study in investigational (experimental).

Full Title of Study: “Preemptive Infusion of Donor Lymphocytes Depleted of TCR (Alpha-beta) + T Cells and CD19+ B Cells Following Allogeneic Stem Cell Transplantation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2022

Detailed Description

The primary objective of this study is to investigate if donor lymphocytes depleted of TCR-αβ T cells and B cells can be infused on Day 28 following allogeneic stem cell transplantation without inducing Grade III-IV graft versus host disease, Grade II GVHD requiring systemic treatment and or new onset, severe neutropenia requiring growth factor support. This study also seeks to characterize the lymphocyte subsets obtained following depletion of TCR-αβ T cells and B cells from non-mobilized, leukapheresis products. Additionally, this study will attempt to describe occurrence of disease relapse and to describe the occurrence of post-transplant re- activation and/or infections with viruses such as CMV, and EBV.

Interventions

  • Biological: Cellular therapy product
    • Cellular therapy product: Allogeneic transplant donor lymphocytes, depleted of TCR-αβ T cells and B cells; enriched for NK cells and TCRγδ T cells. Infused using venous catheter on post-transplant Day 28 (+ 7 days). Single infusion of entire lymphocyte product derived from two-blood volume leukapheresis (non-mobilized).

Arms, Groups and Cohorts

  • Experimental: NK/γδ T cell-enriched cell therapy product
    • This study will treat 10 participants with the donor NK/TCR-γδ T cell product. Of those 10 participants, 5 would have 10/10 HLA matched sibling donors (MSD) while 5 would have partially matched, related (haplo) donors. 27 days post transplant, the participant’s donor will undergo a second, non-mobilized leukapheresis to obtain peripheral blood mononuclear cells (PBMCs). Donor PBMCs will be processed next day (Day T+28) to obtain the NK cell/TCRγδ T cell product for same day infusion if the participant remains aGVHD free and clinically stable. Participants will continue routine post-transplant and GVHD monitoring, as well as disease assessment at 56 days, 100 days, 6 months and 1 year following transplant. Blood samples will be obtained on T=0, T+7, 14, 21 and 28 days and then weekly until T + 56 days, then on T+100 days, + 6 months and + 12 months. If immune-mediated adverse events occur (GVHD, CRS etc) additional blood samples will be obtained at onset and resolution.

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of Grade III-IV GVHD, Grade II GVHD requiring systemic treatment or new onset, severe neutropenia requiring growth factor support at Day 100 and T+6 months.
    • Time Frame: up to 30 days after lymphocyte product infusion
    • This study seeks to measure if donor lymphocytes depleted of TCR-αβ T cells and B cells can be infused on Day 28 following allogeneic stem cell transplantation without inducing Grade III-IV graft versus host disease, Grade II GVHD requiring systemic treatment or new onset, severe neutropenia requiring growth factor support. The endpoint associated with this objective is ‘incidence of Grade III-IV graft versus host disease, Grade II GVHD requiring systemic treatment or new onset, severe neutropenia requiring growth factor support at Day 100 and T+6 months.’

Secondary Measures

  • Different lymphocyte types in the infused product reported as cells per kilogram body weight of the recipient
    • Time Frame: 28 days post-transplant
    • Number of different lymphocyte types in the infused product measured as cells per kilogram body weight of the recipient
  • Number of disease relapse events in the first 6 moths following stem cell transplant
    • Time Frame: 6 months from start of treatment
    • To describe occurrence of disease relapse, the number of disease relapse events in the first year following stem cell transplant will be reported.
  • Number of disease relapse events in the first 1 year following stem cell transplant
    • Time Frame: 1 year from start of treatment
    • To describe occurrence of disease relapse, the number of disease relapse events in the first year following stem cell transplant will be reported.
  • Average time to disease relapse from date of transplant
    • Time Frame: 6 months from start of treatment
    • To describe occurrence of disease relapse, the average time to disease relapse from date of transplant in the first six months following stem cell transplant will be reported.
  • Average time to disease relapse from date of transplant
    • Time Frame: 1 year from start of treatment
    • To describe occurrence of disease relapse, the average time to disease relapse from date of transplant in the first year following stem cell transplant will be reported.
  • Occurrence of reactivated Epstein Barr Virus (EBV) and/or Cytomegalovirus viremia (CMV) as measured by number of study subjects developing measurable viremia
    • Time Frame: 6 months from start of treatment
    • To describe the occurrence of post-transplant re- activation and/or infections with viruses such as CMV, and/or EBV, the number of study subjects developing measurable viremia will be reported
  • Average time to first occurrence of reactivated EBV and/or CMV
    • Time Frame: 6 months from start of treatment
    • To describe the occurence of post-transplant re- activation and/or infections with viruses such as CMV, and/or EBV, median time to first occurrence of reactivated EBV and/or CMV will be reported.

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects must have histologic or cytologic confirmation of ANY hematologic malignancy – Allogeneic stem cell transplant is indicated as management of underlying hematologic malignancy. – Participant has organ function (cardiac, lung and liver) considered adequate to undergo conditioning chemotherapy and allogeneic stem cell transplant in the assessment of the clinical program – Participant has a 10/10 HLA-matched sibling donor OR has a HLA-haploidentical donor available (in the absence of a 10/10 HLA matched unrelated donor) – The related transplant donor is willing, available and consents to undergo a second, non-mobilized leukapheresis for the procurement of donor lymphocytes – The related transplant donor is 18 years of age or older – Subjects (or their parents if participant is younger than 18 years old) must have the ability to understand and the willingness to sign a written informed consent document or provide assent. Exclusion Criteria:

  • Subject is unwilling to receive a prophylactic donor lymphocyte infusion per study protocol. – The related donor is unwilling or unavailable to undergo a second, non- mobilized leukapheresis for the procurement of donor lymphocytes. – Women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry and for the duration of study participation. Women of child-bearing age must have documented negative pregnancy test prior to start of conditioning regimen for stem cell transplantation and a repeat negative pregnancy test prior to infusion of the lymphocyte product.

Gender Eligibility: All

Minimum Age: 1 Year

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Case Comprehensive Cancer Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Folashade Otegbeye, Principal Investigator, University Hospitals Cleveland Medical Center
  • Overall Contact(s)
    • Folashade Otegbeye, MD MPH, 800-641-2422, CTUReferral@UHhospitals.org

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.